強膜炎の世界市場レポート 2025年

強膜炎市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.9％で55億4,000万米ドルに成長します。予測期間の成長は、目に関連する健康状態の有病率の増加、目の健康に対する意識の高まり、ヘルスケア支出の増加、眼科研究の拡大、個別化医療に対する需要の増加、新しい治療オプションの開発に起因しています。主要動向としては、標的生物学的療法の開発、免疫抑制剤製剤の進歩、画像技術の革新、低侵襲診断ツールの採用、個別化医療アプローチの統合、ドラッグデリバリーシステムの改善、AI主導の診断・治療計画ソリューションなどが挙げられます。

自己免疫疾患の有病率の増加は、強膜炎市場の拡大を促進すると予想されます。自己免疫疾患は、身体の免疫システムが自身の健康な細胞や組織を外国の脅威と誤認して攻撃することで発生します。自己免疫疾患の増加は、遺伝的素因、環境の影響、ライフスタイルの変化、診断意識の向上に起因しています。これらの疾患は、強膜組織を誤って標的とする炎症性免疫反応を引き起こし、痛みや発赤を引き起こすことで、強膜炎の一因となっています。例えば、2024年11月、ドイツを拠点とする組織であるVersorgungsatlas.deは、2022年の保険加入者7,324万1,305人のうち、630万4,340人が少なくとも1つの自己免疫疾患と診断されたと報告し、その結果、生の有病率は8.61％となりました。その結果、自己免疫疾患の罹患率の増加が強膜炎市場の拡大に拍車をかけています。

強膜炎市場の主要企業は、炎症に対処し、非侵襲的な治療オプションを提供するために、特殊な点眼薬などの先進治療を開発しています。目薬は、刺激、乾燥、炎症、感染症などの状態を管理するために、眼に直接塗布するように設計された液体製剤です。例えば、2023年5月、インドを拠点とする製薬会社Entod Pharmaceuticalsは、インドと世界でCYCLOTEARS点眼薬を発売しました。この革新的な炎症性眼疾患治療は、独自のSEDDS技術を活用し、ドラッグデリバリーと有効性を高めています。本製品は、ドライアイ（DED）、眼筋炎、強膜炎などの眼炎症性疾患の管理における重要な進歩です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の強膜炎PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の強膜炎市場：成長率分析
• 世界の強膜炎市場の実績：規模と成長、2019～2024年
• 世界の強膜炎市場の予測：規模と成長、2024～2029年、2034年
• 世界の強膜炎総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の強膜炎市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 前部強膜炎
• 後部強膜炎
• その他
• 世界の強膜炎市場：治療別、実績と予測、2019～2024年、2024～2029年、2034年
• 薬
• 手術
• その他
• 世界の強膜炎市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 直接入札
• 病院薬局
• 小売薬局
• オンライン薬局
• その他
• 世界の強膜炎市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 専門クリニック
• 在宅ヘルスケア
• その他
• 世界の強膜炎市場、前部強膜炎のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 非壊死性前部強膜炎
• 壊死性前部強膜炎
• 世界の強膜炎市場、後部強膜炎のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 拡散後部強膜炎
• 結節性後部強膜炎
• 強膜炎脈絡膜病変を伴う
• 世界の強膜炎市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 慢性的な強膜炎
• 繰り返し強膜炎
• 感染性強膜炎

第7章 地域別・国別分析

• 世界の強膜炎市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の強膜炎市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 強膜炎市場：競合情勢
• 強膜炎市場：企業プロファイル
  • Pfizer Inc.
  • Johnson & Johnson
  • F. Hoffmann-La Roche Ltd.
  • Bayer AG
  • Novartis AG

第31章 その他の大手企業と革新的企業

• Gilead Sciences Inc.
• Amgen Inc.
• Teva Pharmaceuticals USA Inc.
• Baxter International Inc.
• Boehringer Ingelheim
• Regeneron Pharmaceuticals Inc.
• Fresenius Kabi USA LLC
• Sun Pharmaceutical Industries Ltd.
• Perrigo Company
• Horizon Therapeutics plc
• Aurobindo Pharma Ltd.
• Hikma Pharmaceuticals PLC
• Amneal Pharmaceuticals LLC
• Mallinckrodt Pharmaceuticals
• Alvogen

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 強膜炎市場、2029年：新たな機会を提供する国
• 強膜炎市場、2029年：新たな機会を提供するセグメント
• 強膜炎市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Scleritis is a condition characterized by inflammation of the sclera, the white part of the eye. It is commonly linked to autoimmune diseases and can lead to severe eye pain, redness, and potential vision impairment if left untreated. Proper diagnosis and treatment of scleritis are essential to prevent long-term eye damage. Early medical intervention helps lower the risk of complications, including vision loss.

The primary types of scleritis include anterior scleritis, posterior scleritis, and other forms. Anterior scleritis occurs when the front portion of the sclera, the eye's outer white layer, becomes inflamed, resulting in redness, pain, and swelling around the eyes. Treatment options include medications, surgical procedures, and other therapies. The condition is addressed through various distribution channels, including hospital pharmacies, retail pharmacies, online pharmacies, and other outlets. Additionally, scleritis treatment is provided in healthcare settings such as hospitals, specialty clinics, home healthcare, and other end-user environments.

The scleritis market research report is one of a series of new reports from The Business Research Company that provides scleritis market statistics, including the scleritis industry's global market size, regional shares, competitors with a scleritis market share, detailed scleritis market segments, market trends and opportunities, and any further data you may need to thrive in the scleritis industry. This scleritis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The scleritis market size has grown strongly in recent years. It will grow from $3.60 billion in 2024 to $3.94 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth during the historic period can be attributed to the rising prevalence of autoimmune disorders, increased awareness of ocular health, a growing geriatric population, improved access to ophthalmic care, and the expansion of healthcare infrastructure worldwide.

The scleritis market size is expected to see strong growth in the next few years. It will grow to $5.54 billion in 2029 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to the increasing prevalence of eye-related health conditions, rising awareness of ocular health, growing healthcare expenditure, expanding ophthalmology research, increasing demand for personalized medicine, and the development of new treatment options. Key trends include the development of targeted biologic therapies, advancements in immunosuppressive drug formulations, innovations in imaging technologies, the adoption of minimally invasive diagnostic tools, the integration of personalized medicine approaches, improvements in drug delivery systems, and AI-driven diagnostic and treatment planning solutions.

The increasing prevalence of autoimmune diseases is expected to drive the expansion of the scleritis market. Autoimmune diseases occur when the body's immune system mistakenly attacks its own healthy cells and tissues, perceiving them as foreign threats. The rise in autoimmune diseases is attributed to genetic predispositions, environmental influences, lifestyle changes, and improved diagnostic awareness. These conditions contribute to scleritis by triggering an inflammatory immune response that mistakenly targets scleral tissue, leading to pain and redness. For example, in November 2024, Versorgungsatlas.de, a Germany-based organization, reported that out of 73,241,305 insured individuals in 2022, 6,304,340 were diagnosed with at least one autoimmune disease, resulting in a raw prevalence rate of 8.61%. Consequently, the growing incidence of autoimmune diseases is fueling the expansion of the scleritis market.

Leading companies in the scleritis market are developing advanced treatments, such as specialized eye drops, to address inflammation and provide non-invasive therapeutic options. Eye drops are liquid formulations designed for direct ocular application to manage conditions such as irritation, dryness, inflammation, and infections. For instance, in May 2023, Entod Pharmaceuticals, an India-based pharmaceutical company, introduced CYCLOTEARS eye drops in India and globally. This innovative treatment for inflammatory eye diseases utilizes proprietary SEDDS technology, enhancing drug delivery and efficacy. The product represents a significant advancement in managing ocular inflammatory conditions, including dry eye disease (DED), ocular myositis, and scleritis.

In January 2025, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, acquired Oxular Limited for an undisclosed amount. This acquisition grants Regeneron access to an advanced ocular gene therapy delivery system, accelerating its progress toward clinical applications. By integrating Oxular's proprietary technologies, Regeneron aims to enhance therapeutic precision and drive innovation in eye care. Oxular Limited, a UK-based biotech company, specializes in developing drug and device treatments for eye disorders, including scleritis.

Major players in the scleritis market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceuticals USA Inc., Baxter International Inc., Boehringer Ingelheim, Regeneron Pharmaceuticals Inc., Fresenius Kabi USA LLC, Sun Pharmaceutical Industries Ltd., Perrigo Company, Horizon Therapeutics plc, Aurobindo Pharma Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Mallinckrodt Pharmaceuticals, Alvogen, Accord Healthcare, West-Ward Pharmaceuticals, Jubilant Cadista Pharmaceuticals Inc., Mylan Pharmaceuticals Inc., Zydus Pharmaceuticals Inc.

North America was the largest region in the scleritis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in scleritis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the scleritis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The scleritis market consists of revenues earned by entities by providing services such as ultrasound, biologic therapies, and blood tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The scleritis market includes sales of ophthalmoscopes, nonsteroidal anti-inflammatory drugs, antibiotics, eye shields or patches, and cold or warm compress kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Scleritis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on scleritis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for scleritis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The scleritis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Anterior Scleritis; Posterior Scleritis; Other Types
• 2) By Treatment: Medication; Surgery; Other Treatment
• 3) By Distribution Channel: Direct Tender; Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channel
• 4) By End-Users: Hospitals; Specialty Clinics; Home Healthcare; Other End-Users
• Subsegments:
• 1) By Anterior Scleritis: Non-Necrotizing Anterior Scleritis; Necrotizing Anterior Scleritis
• 2) By Posterior Scleritis: Diffuse Posterior Scleritis; Nodular Posterior Scleritis; Scleritis With Choroidal Involvement
• 3) By Other Types: Chronic Scleritis; Recurrent Scleritis; Infectious Scleritis
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Bayer AG; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Scleritis Market Characteristics

3. Scleritis Market Trends And Strategies

4. Scleritis Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Scleritis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Scleritis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Scleritis Market Growth Rate Analysis
• 5.4. Global Scleritis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Scleritis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Scleritis Total Addressable Market (TAM)

6. Scleritis Market Segmentation

• 6.1. Global Scleritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anterior Scleritis
• Posterior Scleritis
• Other Types
• 6.2. Global Scleritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medication
• Surgery
• Other Treatment
• 6.3. Global Scleritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Direct Tender
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Other Distribution Channel
• 6.4. Global Scleritis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Home Healthcare
• Other End-Users
• 6.5. Global Scleritis Market, Sub-Segmentation Of Anterior Scleritis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Necrotizing Anterior Scleritis
• Necrotizing Anterior Scleritis
• 6.6. Global Scleritis Market, Sub-Segmentation Of Posterior Scleritis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diffuse Posterior Scleritis
• Nodular Posterior Scleritis
• Scleritis With Choroidal Involvement
• 6.7. Global Scleritis Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chronic Scleritis
• Recurrent Scleritis
• Infectious Scleritis

7. Scleritis Market Regional And Country Analysis

• 7.1. Global Scleritis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Scleritis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Scleritis Market

• 8.1. Asia-Pacific Scleritis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Scleritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Scleritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Scleritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Scleritis Market

• 9.1. China Scleritis Market Overview
• 9.2. China Scleritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Scleritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Scleritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Scleritis Market

• 10.1. India Scleritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Scleritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Scleritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Scleritis Market

• 11.1. Japan Scleritis Market Overview
• 11.2. Japan Scleritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Scleritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Scleritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Scleritis Market

• 12.1. Australia Scleritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Scleritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Scleritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Scleritis Market

• 13.1. Indonesia Scleritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Scleritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Scleritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Scleritis Market

• 14.1. South Korea Scleritis Market Overview
• 14.2. South Korea Scleritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Scleritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Scleritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Scleritis Market

• 15.1. Western Europe Scleritis Market Overview
• 15.2. Western Europe Scleritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Scleritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Scleritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Scleritis Market

• 16.1. UK Scleritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Scleritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Scleritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Scleritis Market

• 17.1. Germany Scleritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Scleritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Scleritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Scleritis Market

• 18.1. France Scleritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Scleritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Scleritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Scleritis Market

• 19.1. Italy Scleritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Scleritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Scleritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Scleritis Market

• 20.1. Spain Scleritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Scleritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Scleritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Scleritis Market

• 21.1. Eastern Europe Scleritis Market Overview
• 21.2. Eastern Europe Scleritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Scleritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Scleritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Scleritis Market

• 22.1. Russia Scleritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Scleritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Scleritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Scleritis Market

• 23.1. North America Scleritis Market Overview
• 23.2. North America Scleritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Scleritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Scleritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Scleritis Market

• 24.1. USA Scleritis Market Overview
• 24.2. USA Scleritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Scleritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Scleritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Scleritis Market

• 25.1. Canada Scleritis Market Overview
• 25.2. Canada Scleritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Scleritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Scleritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Scleritis Market

• 26.1. South America Scleritis Market Overview
• 26.2. South America Scleritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Scleritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Scleritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Scleritis Market

• 27.1. Brazil Scleritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Scleritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Scleritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Scleritis Market

• 28.1. Middle East Scleritis Market Overview
• 28.2. Middle East Scleritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Scleritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Scleritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Scleritis Market

• 29.1. Africa Scleritis Market Overview
• 29.2. Africa Scleritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Scleritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Scleritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Scleritis Market Competitive Landscape And Company Profiles

• 30.1. Scleritis Market Competitive Landscape
• 30.2. Scleritis Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Scleritis Market Other Major And Innovative Companies

• 31.1. Gilead Sciences Inc.
• 31.2. Amgen Inc.
• 31.3. Teva Pharmaceuticals USA Inc.
• 31.4. Baxter International Inc.
• 31.5. Boehringer Ingelheim
• 31.6. Regeneron Pharmaceuticals Inc.
• 31.7. Fresenius Kabi USA LLC
• 31.8. Sun Pharmaceutical Industries Ltd.
• 31.9. Perrigo Company
• 31.10. Horizon Therapeutics plc
• 31.11. Aurobindo Pharma Ltd.
• 31.12. Hikma Pharmaceuticals PLC
• 31.13. Amneal Pharmaceuticals LLC
• 31.14. Mallinckrodt Pharmaceuticals
• 31.15. Alvogen

32. Global Scleritis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Scleritis Market

34. Recent Developments In The Scleritis Market

35. Scleritis Market High Potential Countries, Segments and Strategies

• 35.1 Scleritis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Scleritis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Scleritis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer